Acute Lymphoblastic Leukemia With Failed Remission (DBCOND0109713)

Identifiers

Synonyms

Not Available

Associated Data

Indicated Drugs and Targets

Not Available

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT05292664	Venetoclax Basket Trial for High Risk Hematologic Malignancies	Asparaginase Erwinia chrysanthemi Azacitidine Calaspargase pegol Calcium Cortisone Cytarabine Dexamethasone Dexrazoxane Doxorubicin Hydrocortisone Hydrocortisone phosphate Hydrocortisone succinate Leucovorin Methotrexate Venetoclax Vincristine	treatment	1	recruiting
NCT06445803	CD19/CD22 CAR-T Cells in Adults With R/R ALL or NHL	No drug interventions	treatment	1	recruiting
NCT05809284	Determining the Mechanisms of Loss of CAR T Cell Persistence	No drug interventions	Not Available	Not Available	recruiting
NCT05779930	Safety and Feasibility of CD19 CAR T Cells Using CliniMACS Prodigy for Relapsed/Refractory CD19 Positive ALL and NHL	No drug interventions	treatment	0	not_yet_recruiting
NCT04049383	CAR-20/19-T Cells in Patients With Relapsed/Refractory B Cell ALL	No drug interventions	treatment	1	recruiting
NCT06034561	Bortezomib-based Regimen for Refractory or Relapsed Acute Lymphoblastic Leukemia	Bortezomib Dexamethasone Doxorubicin Methotrexate Pegaspargase Vincristine	treatment	2	recruiting
NCT03515200	Treatment With Combination Chemotherapy for Relapsed or Refractory Acute Lymphoblastic Leukemia	Bortezomib Cytarabine Dasatinib Dexamethasone Doxorubicin Hydrocortisone Methotrexate Palbociclib Ruxolitinib	treatment	1	terminated
NCT03919240	CAR-T Cell Therapy Targeting to CD19 for R/R ALL	No drug interventions	treatment	1 / 2	recruiting
NCT03751072	Efficacy and Toxicity of Blinatumomab in the French ATU for Adult BCP-ALL R/R, or With MRD+ (FRENCH-CYTO)	No drug interventions	Not Available	Not Available	unknown_status